PL4148050T3 - Nowy inhibitor wydzielania kwasu i jego zastosowanie - Google Patents
Nowy inhibitor wydzielania kwasu i jego zastosowanieInfo
- Publication number
- PL4148050T3 PL4148050T3 PL21826347.3T PL21826347T PL4148050T3 PL 4148050 T3 PL4148050 T3 PL 4148050T3 PL 21826347 T PL21826347 T PL 21826347T PL 4148050 T3 PL4148050 T3 PL 4148050T3
- Authority
- PL
- Poland
- Prior art keywords
- acid secretion
- secretion inhibitor
- novel acid
- novel
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200073900 | 2020-06-17 | ||
| PCT/KR2021/007572 WO2021256861A1 (ko) | 2020-06-17 | 2021-06-16 | 신규한 산 분비 억제제 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4148050T3 true PL4148050T3 (pl) | 2025-03-17 |
Family
ID=79176045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21826347.3T PL4148050T3 (pl) | 2020-06-17 | 2021-06-16 | Nowy inhibitor wydzielania kwasu i jego zastosowanie |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11767311B2 (pl) |
| EP (1) | EP4148050B1 (pl) |
| JP (1) | JP7404561B2 (pl) |
| KR (2) | KR102432523B1 (pl) |
| CN (1) | CN115884968B (pl) |
| AU (1) | AU2021293694B2 (pl) |
| BR (1) | BR112022025613A2 (pl) |
| CL (1) | CL2022003601A1 (pl) |
| CO (1) | CO2023000396A2 (pl) |
| DO (1) | DOP2022000291A (pl) |
| EC (1) | ECSP23002606A (pl) |
| ES (1) | ES3014815T3 (pl) |
| FI (1) | FI4148050T3 (pl) |
| HU (1) | HUE070031T2 (pl) |
| MX (1) | MX2022016515A (pl) |
| PE (1) | PE20231652A1 (pl) |
| PH (1) | PH12022553498A1 (pl) |
| PL (1) | PL4148050T3 (pl) |
| PT (1) | PT4148050T (pl) |
| TW (2) | TWI797645B (pl) |
| WO (1) | WO2021256861A1 (pl) |
| ZA (1) | ZA202213152B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4148050T (pt) | 2020-06-17 | 2025-01-29 | Ildong Pharmaceutical Co Ltd | Novo inibidor da secreção ácida e sua utilização |
| WO2023113458A1 (en) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof |
| WO2023113474A1 (ko) * | 2021-12-15 | 2023-06-22 | 일동제약(주) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| KR20230102353A (ko) * | 2021-12-30 | 2023-07-07 | 주식회사 대웅제약 | 삼중음성유방암의 예방 또는 치료용 약학적 조성물 |
| CN114539219A (zh) * | 2022-03-17 | 2022-05-27 | 日照正济药业有限公司 | 一种富马酸伏诺拉生的制备方法 |
| WO2023211843A1 (en) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions |
| TW202411216A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | ６－甲氧基吡啶－３－基衍生物之製造方法 |
| KR102975773B1 (ko) * | 2022-05-23 | 2026-06-10 | 일동제약(주) | 6-메톡시피리딘-3-일 유도체의 제조방법 |
| WO2025023734A1 (en) * | 2023-07-26 | 2025-01-30 | Yunovia Co., Ltd. | Method for preparing intermediates of 6-methoxypyridine-3-yl derivatives |
| KR20260020368A (ko) * | 2024-08-02 | 2026-02-11 | 일양약품주식회사 | 4-사이클로프로필 피롤 유도체 및 이의 용도 |
| KR20260082181A (ko) | 2024-11-27 | 2026-06-04 | (주) 팜젠사이언스 | 신규한 피롤 유도체 화합물 및 이를 포함하는 위산분비 억제용 약제학적 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1514870A4 (en) * | 2002-06-14 | 2006-08-23 | Takeda Pharmaceutical | PRODRUG AND METHOD FOR THE PRODUCTION THEREOF |
| JP5173192B2 (ja) * | 2004-09-30 | 2013-03-27 | 武田薬品工業株式会社 | プロトンポンプ阻害薬 |
| KR101115857B1 (ko) * | 2005-08-30 | 2012-04-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 산 분비 억제제로서 1-헤테로시클릴술포닐, 2-아미노메틸,5-(헤테로-) 아릴 치환된 1-ｈ-피롤 유도체 |
| US7994205B2 (en) | 2006-03-31 | 2011-08-09 | Takeda Pharmaceutical Company Limited | Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors |
| US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| NZ591793A (en) * | 2008-08-27 | 2012-11-30 | Takeda Pharmaceutical | Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds |
| WO2010110378A1 (ja) * | 2009-03-26 | 2010-09-30 | 武田薬品工業株式会社 | ピラゾール化合物 |
| NZ703528A (en) * | 2012-06-27 | 2016-08-26 | Takeda Pharmaceutical | Liquid preparations of amines and organic acids stabilized by salts |
| JP6343600B2 (ja) * | 2013-02-28 | 2018-06-13 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
| CN105693693A (zh) * | 2014-11-27 | 2016-06-22 | 江苏柯菲平医药股份有限公司 | 一种吡咯类胃酸分泌和抑制剂化合物盐的制备 |
| CN105985278A (zh) * | 2015-01-27 | 2016-10-05 | 江苏柯菲平医药股份有限公司 | 吡咯磺酰类衍生物、其制备方法及其在医药上的应用 |
| KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| CN106432191A (zh) * | 2015-08-10 | 2017-02-22 | 陕西合成药业股份有限公司 | 一种新的吡咯类衍生物、其制备方法及其在医药上的应用 |
| KR20170113040A (ko) | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| WO2018059455A1 (zh) * | 2016-09-29 | 2018-04-05 | 江苏吉贝尔药业股份有限公司 | 1-[(吡啶-3-基-磺酰基)-1h-吡咯-3-基]甲胺衍生物及其药物组合物和用途 |
| MY200542A (en) | 2017-07-10 | 2024-01-02 | Takeda Pharmaceuticals Co | Preparation comprising vonoprazan |
| CN110396080B (zh) * | 2018-04-24 | 2022-07-08 | 广东东阳光药业有限公司 | 一种富马酸沃诺拉赞代谢物及其氘代物的制备方法 |
| CN108558831B (zh) * | 2018-06-08 | 2021-07-27 | 上海璃道医药科技有限公司 | 取代吡咯-4-烷基胺类化合物及其用途 |
| PT4148050T (pt) | 2020-06-17 | 2025-01-29 | Ildong Pharmaceutical Co Ltd | Novo inibidor da secreção ácida e sua utilização |
| CN111943932B (zh) * | 2020-08-06 | 2023-07-14 | 四川国康药业有限公司 | 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途 |
-
2021
- 2021-06-16 PT PT218263473T patent/PT4148050T/pt unknown
- 2021-06-16 WO PCT/KR2021/007572 patent/WO2021256861A1/ko not_active Ceased
- 2021-06-16 JP JP2022577797A patent/JP7404561B2/ja active Active
- 2021-06-16 FI FIEP21826347.3T patent/FI4148050T3/fi active
- 2021-06-16 PH PH1/2022/553498A patent/PH12022553498A1/en unknown
- 2021-06-16 PL PL21826347.3T patent/PL4148050T3/pl unknown
- 2021-06-16 AU AU2021293694A patent/AU2021293694B2/en active Active
- 2021-06-16 EP EP21826347.3A patent/EP4148050B1/en active Active
- 2021-06-16 PE PE2022002955A patent/PE20231652A1/es unknown
- 2021-06-16 CN CN202180043522.8A patent/CN115884968B/zh active Active
- 2021-06-16 MX MX2022016515A patent/MX2022016515A/es unknown
- 2021-06-16 US US18/011,084 patent/US11767311B2/en active Active
- 2021-06-16 HU HUE21826347A patent/HUE070031T2/hu unknown
- 2021-06-16 KR KR1020210078283A patent/KR102432523B1/ko active Active
- 2021-06-16 ES ES21826347T patent/ES3014815T3/es active Active
- 2021-06-16 BR BR112022025613A patent/BR112022025613A2/pt unknown
- 2021-06-16 KR KR1020210078284A patent/KR20210156235A/ko active Pending
- 2021-06-17 TW TW110122142A patent/TWI797645B/zh active
- 2021-06-17 TW TW112109894A patent/TWI839161B/zh active
-
2022
- 2022-12-05 ZA ZA2022/13152A patent/ZA202213152B/en unknown
- 2022-12-15 CL CL2022003601A patent/CL2022003601A1/es unknown
- 2022-12-15 DO DO2022000291A patent/DOP2022000291A/es unknown
-
2023
- 2023-01-13 CO CONC2023/0000396A patent/CO2023000396A2/es unknown
- 2023-01-16 EC ECSENADI20232606A patent/ECSP23002606A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT4148050T (pt) | Novo inibidor da secreção ácida e sua utilização | |
| IL290106B1 (en) | Crystalline form of ATR inhibitor and its use | |
| IL288381A (en) | Tead inhibitors and their uses | |
| IL288384A (en) | Tead inhibitors and their uses | |
| EP4389738A4 (en) | SOS1-INHIBITOR AND USE THEREOF | |
| ZA202106511B (en) | Jak inhibitor compound and use thereof | |
| EP4056563A4 (en) | COMPOUND AS A SHP2 INHIBITOR AND USE THEREOF | |
| EP4349838A4 (en) | WEE1 INHIBITOR AND ITS USE | |
| IL307187A (en) | MK2 inhibitors and their uses | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| IL285595A (en) | Spt5 inhibitors and uses thereof | |
| EP4378938A4 (en) | NEW PARP7 INHIBITOR AND USE THEREOF | |
| IL289649A (en) | Formulations of rbp4 inhibitors and methods of use | |
| IL313081A (en) | New HDAC inhibitors and their medical use | |
| IL310209A (en) | ROCK2 inhibitors and their uses | |
| IL273922A (en) | D-amino acid oxidase inhibitors and their therapeutic uses | |
| IL305789A (en) | USP30 inhibitors and uses thereof | |
| IL314049A (en) | PARP7 inhibitors | |
| EP4186908C0 (en) | JAK INHIBITOR COMPOUND AND ITS USE | |
| IL312466A (en) | PI3K-alpha inhibitors and methods for their preparation and use | |
| IL311588A (en) | LPXC inhibitors and their uses | |
| EP4338737A4 (en) | PARP7 INHIBITOR AND ITS USE | |
| GB202002050D0 (en) | Refrigerant compositions and use thereof | |
| IL310370A (en) | Inhibitors of protein expression | |
| GB202307065D0 (en) | Novel compounds and uses thereof |